finanzen.net
26.04.2019 12:45
Bewerten
(0)

Global Viral Vector Manufacturing Markets Report 2019:The Market Accounted for $227.63 Million in 2017 and is Expected to Reach $1013 Million by 2026

DRUCKEN

DUBLIN, April 26, 2019 /PRNewswire/ -- The "Viral Vector Manufacturing - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Global Viral Vector Manufacturing market accounted for $227.63 million in 2017 and is expected to reach $1013 million by 2026 growing at a CAGR of 18.0% during the forecast period.

The increasing prevalence of target diseases and disorders, a rising number of clinical studies and availability of funding for gene therapy development, and potential applications in novel drug delivery approaches are some of the factors propelling the market growth. However, the excessive cost of gene therapies and possible mutagenesis impede the market.

Viral Vector Manufacturing comprises the generation of these vectors, which then have to be purified in order to meet the quality attributes required for further use as gene delivery systems. Viral or non-viral vector methods are used the inefficient transfer of the therapeutic gene into the target cells. Viral vectors used in gene therapy include adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral vectors generally depend on delivery of plasmid DNA.

On the basis of application, Gene Therapy segment holds the significant growth during the forecast period due to the availability of effective viral vector gene therapies for rare diseases & cancers, ongoing research activities on viral vector gene therapies.

Based on geography, North America holds the major market share during the forecast period owing to rise in research activities, a large number of regenerative medicine companies, increase in the prevalence of target diseases and availability of funds.

Some of the key players profiled in the Viral Vector Manufacturing Market include Spark Therapeutics, Uniqure, Kaneka Eurogentec, Regenxbio, Finvector Vision Therapies, Novasep, Massbiologics, Merck KGaA, Cobra Biologics, Fujifilm Holdings Corporation, Lonza, Brammer Bio, Oxford Biomedica and Thermo Fisher Scientific Inc.

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.5 Research Sources

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Viral Vector Manufacturing Market, By Type
5.1 Introduction
5.2 Adenoviral Vectors
5.3 Retroviral Vectors
5.3.1 Gamma-Retroviral Vectors
5.3.2 Lentiviral Vectors
5.4 Adeno-Associated Viral Vectors
5.5 Pox Virus
5.6 Cytomegalovirus
5.7 Other Types
5.7.1 Herpes Simplex Virus Vectors

6 Global Viral Vector Manufacturing Market, By Disease
6.1 Introduction
6.2 Human Disease
6.2.1 Infectious Diseases
6.2.1.1 Influenza
6.2.1.2 Malaria
6.2.1.3 Hepatitis
6.2.2 Genetic Disorders
6.2.2.1 Human Immunodeficiency Virus (HIV)
6.2.2.2 Tuberculosis
6.2.3 Cancer
6.2.4 Other Human Diseases
6.3 Veterinary Disease
6.3.1 Avian Influenza
6.3.2 Marek's Disease
6.3.3 Infectious Bronchitis
6.3.4 Peste des Petits Ruminants (PPR) Disease
6.3.5 Other Veterinary Diseases
6.3.5.1 Rabies
6.3.5.2 Fibromuscular Dysplasia (FMD)
6.3.5.3 Swine Influenza
6.3.5.4 Equine Influenza
6.3.5.5 Newcastle Disease

7 Global Viral Vector Manufacturing Market, By Application
7.1 Introduction
7.2 Vaccinology
7.2.1 Multivalent Vaccines
7.2.2 Multipathogen Vaccines
7.3 Gene Therapy

8 Global Viral Vector Manufacturing Market, By End User
8.1 Introduction
8.2 Research Institutes
8.3 Pharmaceutical and Biopharmaceutical Companies
8.4 Other End Users

9 Global Viral Vector Manufacturing Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Spark Therapeutics
11.2 Uniqure
11.3 Kaneka Eurogentec
11.4 Regenxbio
11.5 Finvector Vision Therapies
11.6 Novasep
11.7 Massbiologics
11.8 Merck KGaA
11.9 Cobra Biologics
11.10 Fujifilm Holdings Corporation
11.11 Lonza
11.12 Brammer Bio
11.13 Oxford Biomedica
11.14 Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/9h725

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-viral-vector-manufacturing-markets-report-2019the-market-accounted-for-227-63-million-in-2017-and-is-expected-to-reach-1013-million-by-2026--300838435.html

SOURCE Research and Markets

Effektiver Vermögensausbau

Mit 12 Wertpapieren langfristig und erfolgreich Vermögen aufzubauen? Wie Sie so erfolgreich investieren, erklärt Börsenprofi Tobias Kramer heute Abend live im Webinar.
Jetzt kostenlos anmelden!
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX tiefer -- Asiens Börsen uneinheitlich -- thyssenkrupp-Aufsichtsrat berät neues Konzern-Konzept -- Wollten Deutsche-Bank-Mitarbeiter Trump-Transaktionen melden?

Google schränkt Zusammenarbeit mit Huawei ein. thyssenkrupp-Aufsichtsrat berät neues Konzern-Konzept. OPEC will zusammen mit Verbündeten Ölreserven verringern. Grand City Properties bleibt auf Wachstumskurs. T-Mobile US und Sprint sind wohl zu weiteren Zugeständnissen bereit. Daimler dementiert Bericht über drohende Rückrufe in Dieselaffäre. Lufthansa-Großaktionär Lansdowne Partners stockt auf.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Bundesjustizministerin Barley (SPD) hat vorgeschlagen, die Mietpreisbremse zu verschärfen. Was halten Sie von dieser Idee?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
Huawei TechnologiesHWEI11
Apple Inc.865985
Amazon906866
TeslaA1CX3T
Scout24 AGA12DM8
BayerBAY001
NEL ASAA0B733
Allianz840400
BMW AG519000
CommerzbankCBK100
BASFBASF11
Volkswagen (VW) AG Vz.766403